Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $919,000.00 in Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total transaction of $919,000.00. Following the completion of the sale, the director now owns 3,580,857 shares of the company’s stock, valued at $164,540,379.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Simulations Plus Trading Down 0.0 %

Shares of Simulations Plus stock opened at $46.70 on Friday. The firm has a fifty day simple moving average of $44.03 and a 200-day simple moving average of $41.18. Simulations Plus, Inc. has a 1-year low of $32.69 and a 1-year high of $52.69. The stock has a market capitalization of $933.53 million, a price-to-earnings ratio of 88.11 and a beta of 0.68.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, April 3rd. The technology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Simulations Plus had a net margin of 16.22% and a return on equity of 7.95%. The business had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $17.31 million. During the same period in the previous year, the company earned $0.20 earnings per share. Simulations Plus’s revenue for the quarter was up 16.2% on a year-over-year basis. As a group, research analysts predict that Simulations Plus, Inc. will post 0.67 earnings per share for the current year.

Simulations Plus Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, May 6th. Investors of record on Monday, April 29th will be paid a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Friday, April 26th. Simulations Plus’s payout ratio is currently 45.28%.

Hedge Funds Weigh In On Simulations Plus

Several large investors have recently bought and sold shares of the stock. Illinois Municipal Retirement Fund raised its stake in Simulations Plus by 2.8% during the 4th quarter. Illinois Municipal Retirement Fund now owns 9,647 shares of the technology company’s stock valued at $432,000 after purchasing an additional 263 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its stake in Simulations Plus by 194.5% during the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,487 shares of the technology company’s stock valued at $62,000 after purchasing an additional 982 shares during the last quarter. Canton Hathaway LLC raised its stake in Simulations Plus by 25.0% during the 4th quarter. Canton Hathaway LLC now owns 5,000 shares of the technology company’s stock valued at $224,000 after purchasing an additional 1,000 shares during the last quarter. Campbell & CO Investment Adviser LLC raised its stake in Simulations Plus by 21.7% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 6,089 shares of the technology company’s stock valued at $254,000 after purchasing an additional 1,084 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Simulations Plus by 9.1% during the 1st quarter. BNP Paribas Financial Markets now owns 14,143 shares of the technology company’s stock valued at $582,000 after purchasing an additional 1,174 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.